RxDoctor Payments Data

Ron Chay, MD

Nephrology · Staten Island, NYNPI 1982639324

Payments from drug & device makers

$1,175in general payments, 2019–2025

Across 43 payments — averaging $27.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$769
  • Mozarc Medical US LLC$127
  • Fresenius USA Marketing, Inc.$88
  • Lilly USA, LLC$83
  • Novo Nordisk$52
  • Baxter Healthcare$27
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$1,16299%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,175 in reported general payments places this provider in the 55th percentile of 935 nephrology providers in New York.

See all nephrology providers in New York

Medicare billing

Part B allowed, 2024
$647,627
Medicare patients
526
Services billed
3,782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol133$194,212
JardianceEmpagliflozin83$113,597
MounjaroTirzepatide78$101,313
OzempicSemaglutide36$67,755
LokelmaSodium Zirconium Cyclosilicate37$44,789
JanuviaSitagliptin Phosphate37$33,861
JanumetSitagliptin Phos/Metformin Hcl16$18,531
VeltassaPatiromer Calcium Sorbitex13$16,226
TradjentaLinagliptin11$15,953
Tresiba Flextouch U-200Insulin Degludec16$15,525
Calcium Acetate64$6,850
JentaduetoLinagliptin/Metformin Hcl12$6,201
Sevelamer Carbonate13$3,822
Potassium Citrate ErPotassium Citrate28$3,668
Midodrine Hcl14$1,660

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$769$239,001170 claims
Lilly USA, LLCMounjaro$83$101,31378 claims
Novo NordiskOzempic$52$67,75536 claims
MerckJanuvia, Janumet$16$52,39253 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 935 nephrology providers in New York.

Other nephrology in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →